Proteomic and Phosphoproteomic Maps of Lung Squamous Cell Carcinoma From Chinese Patients
文献类型：期刊论文
| 作者 | Pan, Lulu1,2; Wang, Xijun3; Yang, Longhai4,5; Zhao, Lei1; Zhai, Linhui1; Xu, Junyu1; Yang, Yikun4; Mao, Yousheng4; Cheng, Shujun3; Xiao, Ting3 |
| 刊名 | FRONTIERS IN ONCOLOGY
 |
| 出版日期 | 2020-06-16 |
| 卷号 | 10页码:13 |
| ISSN号 | 2234-943X |
| 关键词 | lung squamous cell carcinoma proteomics phosphoproteomics clustering lymph node metastasis cell cycle |
| DOI | 10.3389/fonc.2020.00963 |
| 通讯作者 | Xiao, Ting(xiaot@cicams.ac.cn) ; Tan, Minjia(mjtan@simm.ac.cn) |
| 英文摘要 | Lung squamous cell carcinoma (LUSC) is one of the leading causes of tumor-driven deaths in the world. To date, studies on the tumor heterogeneity of LUSC at genomic level have only revealed limited therapeutic benefits. Therefore, system-wide research of LUSC at proteomic level may further improve precision medicine strategies on individual demands. To this end, we performed proteomic and phosphoproteomic study for LUSC samples of 25 Chinese patients. From our results, two subgroups (Cluster I and II) based on proteomic data were identified, which were associated with distinct molecular characteristics and clinicopathologic features. Combined with phosphoproteomic data, our result showed that spliceosome pathway was enriched in Cluster I, while focal adhesion pathway, immune-related pathways and Ras signaling pathway were enriched in Cluster II. In addition, we found that lymph node metastasis (LNM) was associated with our proteomic subgroups and cell cycle pathway was enriched in patients with LNM. Further analysis showed that MCM2, a DNA replication licensing factor involved in cell cycle pathway, was highly expressed in patients with poor prognosis, which was further proved by immunohistochemistry (IHC) analysis. In summary, our study provided a resource of the proteomic and phosphoproteomic features of LUSC in Chinese patients. |
| WOS关键词 | CANCER STATISTICS ; EXPRESSION ; REVEALS ; PHOSPHORYLATION ; BIOSYNTHESIS ; ENRICHMENT ; MUTATIONS ; PROTEINS ; TARGET ; GENES |
| 资助项目 | Natural Science Foundation of China[81872888] ; Natural Science Foundation of China[81821005] ; National Basic Research Program of China (973 Program)[2014CBA02004] ; National Science and Technology Major Project Key New Drug Creation and Manufacturing Program[2018ZX09711002-004] ; CAMS Innovation Fund for Medical Sciences (CIFMS) of China[2016-I2M1-001] ; CAMS Innovation Fund for Medical Sciences (CIFMS) of China[2019-I2M-1-003] ; National Key Research and Development Program of China[2017YFC0908401] ; Innovation research team of high-level local universities in Shanghai[SSMU-ZDCX20181202] ; K. C. Wong Education Foundation |
| WOS研究方向 | Oncology |
| 语种 | 英语 |
| 出版者 | FRONTIERS MEDIA SA |
| WOS记录号 | WOS:000546878000001 |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/291821]  |
| 专题 | 新药研究国家重点实验室 |
| 通讯作者 | Xiao, Ting; Tan, Minjia |
| 作者单位 | 1.Chinese Acad Sci, Chem Prote Ctr, Shanghai Inst Mat Media, State Key Lab Drug Res, Shanghai, Peoples R China 2.Univ Chinese Acad Sci, Sch Pharm, Beijing, Peoples R China 3.Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Clin Res Ctr Canc, Natl Canc Ctr,Dept Etiol & Carcinogenesis,State K, Beijing, Peoples R China 4.Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Clin Res Ctr Canc, Natl Canc Ctr,Dept Thorac Surg, Beijing, Peoples R China 5.Shenzhen Univ, Clin Med Acad, Gen Hosp, Dept Cardiothorac Surg, Shenzhen, Peoples R China |
| 推荐引用方式 GB/T 7714 | Pan, Lulu,Wang, Xijun,Yang, Longhai,et al. Proteomic and Phosphoproteomic Maps of Lung Squamous Cell Carcinoma From Chinese Patients[J]. FRONTIERS IN ONCOLOGY,2020,10:13. |
| APA | Pan, Lulu.,Wang, Xijun.,Yang, Longhai.,Zhao, Lei.,Zhai, Linhui.,...&Tan, Minjia.(2020).Proteomic and Phosphoproteomic Maps of Lung Squamous Cell Carcinoma From Chinese Patients.FRONTIERS IN ONCOLOGY,10,13. |
| MLA | Pan, Lulu,et al."Proteomic and Phosphoproteomic Maps of Lung Squamous Cell Carcinoma From Chinese Patients".FRONTIERS IN ONCOLOGY 10(2020):13. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。